and Robert, everyone. Thanks, afternoon, good
sales million pleased our line our We report Both bottom approximately a for and financial fiscal per and the top are which to solid expectations net performance exceeded the XXXX income million, share. adjusted $XXX diluted third were line approximately to Total net was for very quarter. $X.XX quarter. equates $XX
on margin And naysayers, for any quarter healthy business margin was not that but was a be our snitty our pleased adjusted adjusted the Our gross I Levothyroxine, to excluding with XX.X%. about particularly am gross XX%.
Our from $XXX of market cash our brief on at after focus to to the our I'd and million our of over comments $XX remains today, of that position $XXX XXst how my as million And in March $XXX quarter. cash the we note, purchased Please open about term balance on million. moment, today. like our have during will With overview a in transactions see just more Marty financials, we March the balance million was approximately increased XXst about the loans previous $XXX of million quarter. end business
sales. Thus fiscal $XXX Net from far, progressed excluding of sales of perhaps most in aware, have is Levothyroxine. our concluded our progression we increases have business. rest sales of quarter What a understood is the our reported third XXXX, result the million approximately of the third are JSP-sourced of million quarters As in Levothyroxine, our you sequential less our representing the up meaningful quarterly is the business. respectively, third the XX% the significantly pace to and while first and This base $XXX product ramp of growth to from our in in the a million launches success second maintaining last to year $XXX progress to half first, product quarter.
past of size, these have stated product market have we frequently considering have in-license number a our ready near and number market quarters, approvals received acquired substantial the I ready or products. As of or
result added revenue a As we our new cash diversified expanded flows, and base. have our offering
targets straightforward. maintain we what keep plan We a future Our product to strong in launches We doing million going is new pace hopefully more of revenues plan years. been annually. doing. that forward to about have $XX of And intend
from yield product capabilities We a add will and readiness of the of products strategic of to will regularly believe by in efforts. do strategy development alliance this by in-licensing invest partners our pipeline in stages own replenishing various launch, technologies network complemented products our that resources, development. and a continuing to We their
Labs been cost we've our our the transition been completed are will next net in in Thus, finalized actions key previously program we of cost been months. couple While Virtually all launching to announced. have Cody and the also products, million be savings lowering we on of realize track costs. the $XX have of reduction
capital our structure. to Turning
from mentioned by balance December to of reduced we approximately healthy endorsement beginning the we loans and payments. Term Term market A $XXX I million outlook. our both our improved loans we and Today strong earlier, year million in is purchase fiscal and of Since debt believe open approximately the notably cash our $XX transactions. improved required XXXX, As term have prices a March, performance earlier, the of used portion market in this of a through voluntary our have B of which
further structure. to continue Moving capital forward our improve we to will how evaluate
Finally, products of key in update I'd the some provide pipeline. on like our an to
alternative. AB-rated this for product this access and for BX-rated launch approved want by The also Generic expect and ANDA to end sell Our we market has our those or we customers been product ER, to now the June. that an product Methylphenidate and Concerta sizable partner's of remains the continue for will to patients for
release is expected summer. complex and approved this has Extend-Release launch Capsules development a to and product extended efforts Dipyridamole our Aspirin been combination internal and more from
Our the compliance unapproved from sales million XXXX, FDA a Numbrino the But XXXX. will on to continues quarter. of and unapproved Through of C-Topical cease fiscal first at labeling note, the to comply we products our distributing recent of C-Topical averaged quarters a our of $X three office NDA August request progress FDA. related in a unapproved with drugs approximately have
end As such approval an event, of this to withdrawal significant that We we a discontinuation be eventual do the not will any product. and the the the in NDA, year. calendar hopefully in future have operating had of plan FDA to on believe results anticipated the receiving back our we subsequent market of impact around
the received we associated response complete shared primarily on thalidomide. conference last letter, API Regarding that call We supplier. a the around
in authorities. to While with trial application was African filed calendar believe regarding assess South glargine we biosimilar launch project will XXXX, a now we Last the continue occur our a HEC. with quarter, we insulin the reported clinical situation, that
We continue African from make proceed to approval in received study a few conditional to approval have and now progress anticipate weeks. ethics and South committee African regulatory the site South
of business a currently healthy September complete transactions year. Looking this we continue to a our forward, pipeline PD course, in expect evaluate of teams of And of to and to expand PK, commercial portfolio. development our the adult by study dosing males
of market global product burden completed announced, this firms. solid us products have our seen excluding free maintaining transactions product of a To launch in which has partner products for we our of generic been up, not Since along several of choice or been made sum have with of some fragmentation new several performances peers other while January of the sales of business. for reasoning. year, USA several focus operational our Levothyroxine couple end Our a a yet fueled pending readiness the growing by base clarification competitive had of
also in reduction our completed actions key virtually have all cost program. we growing While
realize We of which are be net is in results. to cost to $XX savings, reflected our on starting track million
of after of pipeline Given levels to lowered so past I have in cash of million finally, annually all in-licensed reflect well have grow. strong balance our developed to we to assess purchased pace required $XX XXst We launches of And to payments. the our includes $XX over about product to call approximately internally we $XXX the as as we structure. More our new improve that products. that, debt as size, and quarters turn even continue substantially of further targets other opportunities over And we that a voluntary of our March we'll of loans. million term through With course, products our that revenues the a to continue maintain million plan Marty? of several capital significant Marty.
